Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/17101945/ below:

Prescription of tamoxifen for breast cancer prevention by primary care physicians

Affiliations

• ¹ Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA. karmstro@mail.med.upenn.edu

• PMID: 17101945
• DOI: 10.1001/archinte.166.20.2260

Item in Clipboard

Katrina Armstrong et al. Arch Intern Med. 2006.

• ¹ Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA. karmstro@mail.med.upenn.edu

• PMID: 17101945
• DOI: 10.1001/archinte.166.20.2260

Item in Clipboard

Background: Although tamoxifen citrate has been approved for primary reduction of breast cancer risk since 1998, little is known about the prescription of tamoxifen by primary care physicians.

Methods: To investigate the determinants of prescription of tamoxifen for breast cancer prevention by primary care physicians, we mailed a national survey to 350 primary care physicians, including specialties of family practice, obstetrics and gynecology, and general internal medicine, regarding past prescription of tamoxifen, intention to prescribe tamoxifen in hypothetical scenarios, and potential predisposing and enabling factors.

Results: Ninety-six physicians (27.4%) reported having prescribed tamoxifen for breast cancer prevention at least once in the prior 12 months. After multivariate adjustment, having prescribed tamoxifen was associated with the physician having a family member with breast cancer (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.21-5.85), patients who asked for information about tamoxifen (OR, 3.98; 95% CI, 1.44-11.04), and the beliefs that the benefits of tamoxifen outweighed the risks (OR, 1.86; 95% CI, 1.07-3.24) and that eligibility was easy to determine (OR, 2.67; 95% CI, 1.35-5.29). In hypothetical scenarios, the prescription of tamoxifen was affected by the patient's family history of breast cancer but not by her risk for endometrial cancer (ie, hysterectomy status).

Conclusions: A minority of primary care physicians have prescribed tamoxifen for breast cancer prevention. The decision to prescribe tamoxifen is affected by the ability to determine eligibility, patient demand, and personal experience with breast cancer as much as perceptions of the risks and benefits. A woman's risk of endometrial cancer from tamoxifen seems to have less impact on prescribing decisions than the magnitude of her breast cancer risk.

PubMed Disclaimer

• Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.

  Lash TL, Gurwitz JH, Silliman RA. Lash TL, et al. J Am Geriatr Soc. 2005 Nov;53(11):1889-96. doi: 10.1111/j.1532-5415.2005.53562.x. J Am Geriatr Soc. 2005. PMID: 16274369

• Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

  Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Peshkin BN, et al. J Clin Oncol. 2003 Dec 1;21(23):4322-8. doi: 10.1200/JCO.2003.02.107. J Clin Oncol. 2003. PMID: 14645421

• Factors affecting breast cancer risk reduction practices among California physicians.

  Kaplan CP, Haas JS, Pérez-Stable EJ, Des Jarlais G, Gregorich SE. Kaplan CP, et al. Prev Med. 2005 Jul;41(1):7-15. doi: 10.1016/j.ypmed.2004.09.041. Epub 2004 Dec 10. Prev Med. 2005. PMID: 15916987

• Providing accurate information to women about tamoxifen therapy for breast cancer: current indications, effects, and controversies.

  Pasacreta JV, McCorkle R. Pasacreta JV, et al. Oncol Nurs Forum. 1998 Oct;25(9):1577-83. Oncol Nurs Forum. 1998. PMID: 9802053 Review.

• The thoughts of physicians regarding the need to start hormone replacement therapy in breast cancer survivors.

  Trinh XB, Van Hal G, Weyler J, Tjalma WA. Trinh XB, et al. Eur J Obstet Gynecol Reprod Biol. 2006 Feb 1;124(2):207-11. doi: 10.1016/j.ejogrb.2005.07.009. Epub 2005 Sep 6. Eur J Obstet Gynecol Reprod Biol. 2006. PMID: 16143444 Review.

• Implementation-effectiveness trial of systematic family health history based risk assessment and impact on clinical disease prevention and surveillance activities.

  Wu RR, Myers RA, Neuner J, McCarty C, Haller IV, Harry M, Fulda KG, Dimmock D, Rakhra-Burris T, Buchanan A, Ginsburg GS, Orlando LA. Wu RR, et al. BMC Health Serv Res. 2022 Dec 6;22(1):1486. doi: 10.1186/s12913-022-08879-2. BMC Health Serv Res. 2022. PMID: 36474257 Free PMC article.

• Critical gaps in knowledge and implementation of recommendations by the US Preventive Services Task Force.

  Kelly K, Parente DJ. Kelly K, et al. Prev Med Rep. 2023 Jan 28;32:102120. doi: 10.1016/j.pmedr.2023.102120. eCollection 2023 Apr. Prev Med Rep. 2023. PMID: 36816763 Free PMC article.

• An Effective Multimodal Curriculum to Teach Internal Medicine Residents Evidence-Based Breast Health.

  Corbelli J, Bonnema R, Rubio D, Comer D, McNeil M. Corbelli J, et al. J Grad Med Educ. 2014 Dec;6(4):721-5. doi: 10.4300/JGME-D-14-00257.1. J Grad Med Educ. 2014. PMID: 26140125 Free PMC article.

• Tamoxifen for women at high risk of breast cancer.

  Nazarali SA, Narod SA. Nazarali SA, et al. Breast Cancer (Dove Med Press). 2014 Feb 17;6:29-36. doi: 10.2147/BCTT.S43763. eCollection 2014. Breast Cancer (Dove Med Press). 2014. PMID: 24648767 Free PMC article. Review.

• Diffusion of breast cancer risk assessment in primary care.

  Guerra CE, Sherman M, Armstrong K. Guerra CE, et al. J Am Board Fam Med. 2009 May-Jun;22(3):272-9. doi: 10.3122/jabfm.2009.03.080153. J Am Board Fam Med. 2009. PMID: 19429733 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3